**GioTag study: concept**

Tumor cells with activating EGFR mutation

Afatinib

- Selective pressure
- Development of acquired resistance

T790M cells survive

Afatinib resistant tumor

Osimertinib

- Osimertinib resistant cells
- Heterogeneous resistance mechanisms

**GioTag: design and results**

**Patients (n=203):** received first-line afatinib followed by osimertinib after developing T790M-mediated resistance

- N=203 patients with EGFRm+ NSCLC
- Recruited from 10 countries
- 15% of patients had ECOG PS of ≥2
- 10% had stable brain mets
- 59% Caucasian
- 25% Asian
- 9% African American
- Data from electronic health records: 62%
- Manual chart review: 38%

**ECOG PS:** Eastern Cooperative Oncology Group performance status; **EGFRm+:** EGFR mutation-positive; **OS:** overall survival; **TTF:** time to treatment failure.

*Based on an interim update analysis; only electronic health record data have been updated since the primary analysis (Hochmair et al. Future Oncol 2018;14:2861-74). Final analysis due in 2020.*

**All patients (n=203):**

- 28.1 months TTF

**All patients with Del19-positive tumors (n=149):**

- 41.3 months OS overall
- 45.7 months OS Del19